Kidney Cancer

In this video, Nour Abdallah, MD, discusses an abstract she presented at American Urological Association Annual Meeting, about artificial intelligence generation of the RENAL nephrometry score in the treatment of kidney cancer.

CHICAGO — The addition of CBM588 to immune checkpoint inhibitor-based therapy significantly increased PFS and response rates with no impact on stool microbiome diversity among a small cohort of patients with metastatic renal cell carcinoma.

Patients with primary renal cell carcinoma who quit smoking after diagnosis had a 50% lower risk for death than those who continued to smoke, according to study results published in Journal of Clinical Oncology.

The combination of belzutifan and cabozantinib showed promising antitumor activity among patients with previously treated metastatic clear cell renal cell carcinoma, according to data published in The Lancet Oncology.

A single infusion of ALLO-316 provided a high rate of disease control for patients with advanced or metastatic renal cell carcinoma, results from the phase 1 TRAVERSE trial showed.

A combination of lenvatinib and pembrolizumab continued to provide a greater survival benefit than sunitinib among patients with advanced renal cell carcinoma, an updated analysis of the randomized phase 3 CLEAR study showed.

SAN FRANCISCO — Healio spoke with Moshe Ornstein, MD, about the COSMIC-313 trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, highlights findings from the follow-up data of the CheckMate 9ER trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, discusses interim results from the CaboPoint study presented at the annual ASCO Genitourinary Cancers Symposium.